48 results on '"Koshikawa, Yosuke"'
Search Results
2. Predictors of continuation for asenapine from real-world data in patients with schizophrenia
3. Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study
4. Relationship between circulating mitochondrial DNA and microRNA in patients with major depression
5. Characteristics of persistent depression in the long-term: Randomized controlled trial and two-year observational study
6. Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms.
7. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data
8. Effectiveness and Changes in Brain Functions by an Occupational Therapy Program Incorporating Mindfulness in Outpatients with Anxiety and Depression: A Randomized Controlled Trial
9. Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis
10. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT
11. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data.
12. Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale–Japanese version
13. Usefulness of mirtazapine and SSRIs in late-life depression. Post hoc analysis of the GUNDAM study.
14. Influence of Anesthesia on Seizure Quality in Electroconvulsive Therapy: A Retrospective Study at Kansai Medical University
15. Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks
16. Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects
17. Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects
18. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial
19. Disentangling cognitive inflexibility in major depressive disorder: A transcranial direct current stimulation study
20. Pretreatment plasma cytokine levels as potential predictors of short-term remission of depression
21. Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways
22. Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression
23. Association between the Rostral Anterior Cingulate Cortex and Anterior Insula in the Salience Network on Response to Antidepressants in Major Depressive Disorder as Revealed by Isolated Effective Coherence
24. Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder
25. Pre-stimulus Brain Activity Is Associated With State-Anxiety Changes During Single-Session Transcranial Direct Current Stimulation
26. Social cognition and metacognition contribute to accuracy for self-evaluation of real-world functioning in patients with schizophrenia
27. Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study
28. S40THE RELATIONSHIP BETWEEN CIRCULATING MITOCHONDRIAL DNA AND MIRNA IN PATIENTS WITH MAJOR DEPRESSION
29. Pre-stimulus Brain Activity Is Associated With State-Anxiety Changes During Single-Session Transcranial Direct Current Stimulation
30. F44MICRORNA PROFILES AS PREDICTOR OF PHENOTYPIC FEATURES OF THE THERAPEUTIC EFFECT OF MIRTAZAPINE AND SSRI IN MDD PATIENTS
31. Factors contributed to long time course of treatment of major depressive disorder: a randomized controlled trial based two-year longitudinal study.
32. Additional file 1: of Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
33. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
34. The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial
35. HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: A meta-analysis
36. HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis
37. Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study
38. HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia
39. Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients
40. HTR1AGene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia
41. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT
42. The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial
43. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: A 6-month, open-label, randomized, pilot trial
44. HTR1A polymorphisms and clinical efficacy of antipsychotic drug treatment in schizophrenia: A meta-analysis
45. Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients
46. HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in Schizophrenia
47. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial
48. HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.